Our Pricing

Understanding Semaglutide Monthly Cost UK: Complete Pricing Breakdown

Published on: June 03, 2026

If you're researching semaglutide monthly cost UK options, understanding the pricing structure is essential before starting treatment. At Cured Pharmacy, semaglutide-based injections start from £135.00 per month for Wegovy, with transparent upfront pricing and a free clinical assessment by UK-registered prescribers. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) ensures every patient receives genuine MHRA-licensed medications at the lowest guaranteed prices in the UK.

What Determines Semaglutide Monthly Cost UK?

The monthly cost of semaglutide in the UK varies based on several clinical factors. Your prescribed dose escalation schedule, maintenance dose strength, and the specific branded formulation all influence the final price. At Cured Pharmacy, Wegovy (semaglutide) starts from £135.00 monthly, whilst Mounjaro (tirzepatide, a dual GIP/GLP-1 agonist) begins at £135.00 per pen [1].

Semaglutide works by mimicking GLP-1, a natural hormone that regulates appetite and blood sugar levels. In the landmark STEP 1 trial, participants achieved an average 14.9% body weight reduction over 68 weeks when combined with lifestyle modifications [2]. Your UK prescriber will determine your starting dose based on your medical history, current medications, and weight loss goals during the free consultation.

Unlike some online pharmacies that advertise low headline prices but add hidden consultation fees, Cured Pharmacy displays transparent pricing before you begin your assessment. All prescription medications require clinical evaluation by a UK-registered prescriber, ensuring treatment suitability and safety.

Semaglutide vs Tirzepatide: Monthly Cost Comparison

Both semaglutide and tirzepatide are injectable weight loss medications licensed by the MHRA, but they function through different mechanisms. Semaglutide activates GLP-1 receptors exclusively, whilst tirzepatide is the first dual GIP/GLP-1 receptor agonist available in the UK, potentially offering enhanced efficacy [1][3].

In head-to-head analysis, tirzepatide demonstrated superior weight reduction outcomes. The SURPASS-2 trial showed participants on the highest tirzepatide dose achieved approximately 22.5% body weight reduction compared to 6.7% with semaglutide over 40 weeks [3]. However, both medications require gradual dose escalation to minimise gastrointestinal side effects, which affects monthly costs during the initial treatment phase.

At Cured Pharmacy, your prescriber will discuss which medication aligns with your clinical profile and budget. Wegovy may be more cost-effective for patients seeking proven GLP-1 therapy, whilst Mounjaro offers dual-pathway activation for those who may benefit from enhanced metabolic effects.

Dose Escalation and Long-Term Costs

Both medications follow structured dose escalation protocols. Wegovy typically starts at 0.25mg weekly, increasing gradually to a maintenance dose of 2.4mg over 16-20 weeks. Mounjaro begins at 2.5mg weekly, escalating to maintenance doses between 5mg and 15mg depending on individual response and tolerability [1][2].

Your monthly cost remains consistent once you reach your prescribed maintenance dose. Most patients continue treatment for 12-24 months to achieve and maintain clinically significant weight loss, though duration varies based on individual goals and medical guidance from your UK prescriber.

How to Access Semaglutide Through Cured Pharmacy

Accessing semaglutide at Cured Pharmacy requires three straightforward steps. First, complete the free online consultation questionnaire, which takes under three minutes and covers your medical history, current medications, and weight loss objectives. Our UK-registered clinical team reviews every submission individually.

Second, a qualified UK prescriber assesses your suitability for semaglutide-based treatment. If approved, they'll determine your appropriate starting dose and escalation schedule. You'll receive clear instructions on injection technique, storage requirements, and what to expect during treatment. All consultations are conducted by GMC-registered doctors or GPhC-registered prescribers.

Third, once your prescription is issued, our GPhC-registered pharmacy (registration number 9012511) dispenses your medication in discreet packaging. We source only genuine UK-licensed medicines directly from MHRA-approved wholesalers. Delivery is fast and tracked, ensuring your treatment arrives safely and confidentially.

Who Can Use Semaglutide for Weight Loss?

NICE guidelines recommend GLP-1 receptor agonists for adults with a BMI of 30 kg/m² or above, or 27 kg/m² with weight-related comorbidities such as type 2 diabetes, hypertension, or obstructive sleep apnoea [4]. Your prescriber will calculate your BMI during the consultation and assess whether semaglutide is clinically appropriate.

Certain medical conditions may contraindicate semaglutide use, including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe gastrointestinal disease. Pregnant or breastfeeding women should not use semaglutide. Full eligibility criteria are reviewed during your clinical assessment.

Understanding Semaglutide Side Effects and Management

The most common side effects of semaglutide are gastrointestinal: nausea, diarrhoea, constipation, and abdominal discomfort. In the STEP trials, approximately 44% of participants reported nausea, though most cases were mild to moderate and resolved within weeks [2]. Starting at a low dose and escalating gradually significantly reduces the likelihood of severe symptoms.

To minimise side effects, eat smaller, more frequent meals, avoid high-fat foods, and stay well-hydrated. If nausea persists, your prescriber may recommend slowing your dose escalation or prescribing anti-nausea medication. Serious side effects such as pancreatitis, gallbladder problems, or severe allergic reactions are rare but require immediate medical attention.

At Cured Pharmacy, our clinical team provides ongoing support throughout your treatment journey. You can contact our pharmacists directly on (+44) 116 4646009 if you experience concerning symptoms or have questions about managing side effects. Never discontinue treatment abruptly without consulting your prescriber.

Maximising Weight Loss Results with Semaglutide

Semaglutide is most effective when combined with sustainable lifestyle modifications. Clinical trials demonstrating significant weight loss all included dietary counselling and increased physical activity [2][3]. Aim for a balanced, reduced-calorie diet rich in vegetables, lean proteins, and whole grains, whilst limiting processed foods and added sugars.

Regular physical activity enhances weight loss outcomes and improves cardiovascular health. NICE recommends at least 150 minutes of moderate-intensity aerobic activity weekly, such as brisk walking, cycling, or swimming. Resistance training twice weekly helps preserve lean muscle mass during weight loss, supporting long-term metabolic health.

Track your progress using objective measures beyond the scale. Take baseline measurements, progress photographs, and note improvements in energy levels, sleep quality, and mobility. Most patients notice appetite reduction within the first week, with measurable weight loss appearing by week four. Clinically significant results (5% or more body weight reduction) typically occur within 12-16 weeks at therapeutic doses.

When to Expect Results

Weight loss trajectory varies individually, but clinical trials provide useful benchmarks. In STEP 1, participants lost an average of 6% body weight by week 20, increasing to 14.9% by week 68 [2]. Early responders who achieve at least 5% weight loss within the first 12 weeks are more likely to reach their long-term goals.

Your prescriber will schedule follow-up assessments to monitor progress and adjust treatment as needed. If you haven't achieved at least 5% weight loss after 12-16 weeks at the maintenance dose, your prescriber may reassess your treatment plan or explore alternative options such as tirzepatide or combination therapies.

Alternative Weight Loss Treatments at Cured Pharmacy

Beyond semaglutide-based injections, Cured Pharmacy offers several MHRA-licensed weight loss medications to suit different clinical needs and budgets. Saxenda (liraglutide) is a daily GLP-1 injection starting from £135.00 suitable for patients who prefer daily dosing or have previously responded well to liraglutide for diabetes management.

For patients seeking oral alternatives, Orlistat is a lipase inhibitor that reduces dietary fat absorption. Available from £135.00 monthly, Orlistat works differently from GLP-1 medications by blocking approximately 30% of fat intake from being absorbed [5]. It's particularly suitable for patients who cannot tolerate injections or have contraindications to GLP-1 therapy.

Mysimba combines naltrexone and bupropion to reduce appetite and food cravings through central nervous system pathways. Starting from £135.00, Mysimba offers an alternative mechanism for patients who haven't responded to other treatments or prefer oral medication. Your UK prescriber will discuss all suitable options during your consultation, ensuring you receive the most appropriate treatment for your individual circumstances.

All prescription weight loss medications at Cured Pharmacy require clinical assessment by a UK-registered prescriber. We guarantee genuine UK-licensed products, discreet packaging, and the lowest prices in the UK. Our transparent pricing means you see exact costs before completing your consultation, with no hidden fees or surprise charges.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
4. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity. Technology appraisal guidance [TA875]. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
5. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on multiple factors including adherence to treatment, diet, and physical activity.